hit counter

Detecting Misdiagnosed Bipolar Disorder via MRI Brain Connectivity Analysis (2024 Study)

Bipolar Disorder (BD) and Major Depressive Disorder (MDD) are two of the most prevalent mood disorders, yet they are often misdiagnosed due to overlapping symptoms. This misdiagnosis can lead to inadequate treatment and worsened patient outcomes. However, recent advances in functional magnetic resonance imaging (fMRI) offer a promising solution to this challenge. By analyzing brain …

Read more

Non-Invasive Brain Stimulation for Bipolar Disorder: Effective & Tolerable in Early Studies (2023)

Non-invasive brain stimulation (NIBS) presents a promising frontier for treating bipolar disorder, offering potential alternatives or adjuncts to conventional pharmacotherapy. Emerging evidence suggests that certain non-invasive brain stimulation protocols may help manage symptoms of bipolar disorder. Highlights: Efficacy: Certain NIBS modalities, like anodal tDCS over F3 plus cathodal tDCS over F4, have shown significant improvement …

Read more

Antidepressants May Trigger Mania In Bipolar Disorder via Mitochondria

Antidepressants, commonly used to treat major depressive episodes in bipolar disorder, might have more profound effects on our body’s energy factories, the mitochondria, than previously understood. A recent study examined how certain antidepressants alter mitochondrial energetics, potentially influencing the risk of treatment-emergent mania in bipolar disorder patients. Highlights: Antidepressants Double Edged Sword: While crucial for …

Read more

Adjunct Celecoxib for Depression & Mania: Treatment with a COX-2 Inhibitor

Celecoxib, a selective COX-2 inhibitor, shows promise as an effective and safe adjunct treatment for major depression and mania, according to a new comprehensive systematic review. The analysis also found celecoxib improved symptoms when used as a standalone antidepressant in patients with somatic disorders. However, evidence for efficacy in bipolar depression remains unclear. Key Facts: …

Read more

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder.  In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient.  The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …

Read more

3 New Bipolar Medications (2015): Drugs In Clinical Trials

Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania).  For a period of time, an individual with bipolar disorder will experience debilitating bouts of depression – and often unexpectedly, their entire neurophysiology will shift to facilitate a state of mania (elevated mood).  Diagnostically, there are multiple types …

Read more